

Form PTO-1595 (Rev. 09/04)  
OMB No. 0651-0027 (exp. 6/30/2005)

U.S. DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

### RECORDATION FORM COVER SHEET PATENTS ONLY

Attorney Docket No.:  
01662/75605

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

#### 1. Name of conveying party(ies)/Execution Date(s):

Sigalit LEVI  
Valerie NIDDAM-HILDESHEIM  
Tamas KOLTAI

Execution Date(s) 03JUL07, 25JUN07, 03JUL07

Additional name(s) of conveying party(ies) attached?  Yes  No

#### 2. Name and address of receiving party(ies)

Name: TEVA PHARMACEUTICAL INDUSTRIES LTD

Internal Address: \_\_\_\_\_

Street Address: 5 Basel Street, P.O. Box 3190

City: Petah Tiqva

State: \_\_\_\_\_

Country: Israel Zip: 49131

Additional name(s) & address(es) attached?  Yes  No

#### 3. Nature of conveyance:

- Assignment  Merger
- Security Agreement  Change of Name
- Government Interest Assignment
- Executive Order 9424, Confirmatory License
- Other \_\_\_\_\_

#### 4. Application or patent number(s):

This document is being filed together with a new application.

A. Patent Application No.(s)  
11/788,034

B. Patent No.(s)

Additional numbers attached?  Yes  No

#### 5. Name and address to whom correspondence concerning document should be mailed:

Name: Willem F.C. de Weerd

Internal Address: \_\_\_\_\_

KENYON & KENYON LLP

Street Address: ONE BROADWAY

City: NEW YORK

State: NEW YORK Zip: 10004

Phone Number: 212-425-7200

Fax Number: 212-425-5288

Email Address: \_\_\_\_\_

#### 6. Total number of applications and patents involved:

01

#### 7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00

- Authorized to be charged by credit card
- Authorized to be charged to deposit account
- Enclosed
- None required (government interest not affecting title)


#### 8. Payment Information

a. Credit Card Last 4 Numbers \_\_\_\_\_  
Expiration Date \_\_\_\_\_

b. Deposit Account Number 11-0600

Authorized User Name \_\_\_\_\_

#### 9. Signature:

  
Signature

8/15/2007  
Date

Willem F.C. de Weerd Reg. 51,613

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents:

03

Documents to be recorded (including cover sheet) should be faxed to (703) 306-5995, or mailed to:  
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

CH \$40.00 110600 11788034

01662/75605

**ASSIGNMENT**

WHEREAS, We,

**Name:** Sigalit **LEVI**  
**Address:** 87 Shimon Street, Modi'in,  
 Israel  
**Citizenship:** Israeli

**Name:** Valerie **NIDDAM-HILDESHEIM**  
**Address:** Kadima 60920, P.O. Box 3948,  
 Israel  
**Citizenship:** Israeli

**Name:** Tamas **KOLTAI**  
**Address:** 4 Spiegelmann Street, Netanya 42758  
 Israel  
**Citizenship:** Israeli

have made an invention comprising new and useful improvements in **CRYSTAL FORMS OF O-DESMETHYLVENLAFAXINE** for which a patent application for Letters Patent of the United States of America and other countries, was filed on April 17, 2007 as Serial No. 11/788,034, and claims the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE (day, month, year)
60/792,801	17 April 2006
60/796,739	1 May 2006
60/899,166	1 February 2007
60/902,418	20 February 2007
60/872,955	4 December 2006
60/903,988	27 February 2007

WHEREAS **TEVA PHARMACEUTICAL INDUSTRIES LTD.**, having a place of business at **5 Basel Street, P.O. Box 3190, Petah Tiqva 49131, Israel**, and who, together with its successors and assigns, is hereinafter called "Assignee," is desirous of acquiring the title, rights, benefits, and privileges in the patent application hereinafter recited,

NOW, THEREFORE, for good and valuable consideration furnished by Assignee to us, receipt and sufficiency of which we hereby acknowledge, we hereby, without reservations:

1. Assign, transfer, and convey to Assignee the entire right, title, and interest in and to said invention, said patent application for Letters Patent of the United States of America, any and all

01662/75605

other applications for Letters Patent on said invention in any and all countries, including all divisional, renewal, substitute, continuation, and Convention applications based in whole or in part upon said invention, or upon said patent application, and any and all Letters Patent, reissues, and extensions of Letters Patent granted for said invention or upon said patent application, and every priority right that is or may be predicated upon or arise from said invention, said patent application, and said Letters Patent(s).

2. Authorize Assignee to file patent applications in any or all countries for said invention in our name or in the name of Assignee or otherwise as Assignee may deem advisable, under an International Convention or otherwise.


3. Authorize and request the Commissioner of Patents and Trademarks of the United States of America and the empowered officials of all other governments to issue or transfer all said Letters Patent to Assignee, as Assignee of the entire right, title, and interest therein or otherwise as Assignee may direct.

4. Warrant that we have not conveyed to others any right, title, or interest in said invention, patent application, or patents or any license to use the same or to make, use, or sell anything embodying or utilizing any of said invention; that we have good right to assign the same to Assignee without encumbrance; and that we are aware of no claim to the contrary

5. Bind our heirs, legal representatives, and assigns, as well as ourselves to do, upon Assignee's request and at Assignee's expense, but without additional consideration to us or them, all acts reasonably serving to assure that the said inventions and discoveries, the said patent applications, and the said Letters Patent shall be held and enjoyed by Assignee as fully and entirely as the same could have been held and enjoyed by us, our heirs, legal representatives, and assigns if this assignment had not been made; and particularly to execute and deliver to Assignee all lawful application documents including petitions, specifications, and oaths, and all assignments, disclaimers, and lawful affidavits in form and substance as may be requested by Assignee; to communicate to Assignee all facts known to us relating to said inventions and discoveries or the history thereof; to furnish Assignee with any and all documents, photographs, models, samples, and other physical exhibits in our control or in the control of our heirs, legal representatives, or assigns which may be useful for establishing the facts of our conceptions, disclosures, and reduction to practice of said inventions and discoveries; and to testify to the same in any interference, arbitration, or litigation.


IN TESTIMONY WHEREOF, we have hereunto set our hands and seals on the dates indicated:

Date: 5/7/07




\_\_\_\_\_  
Sigalit LEVI

Date: 25-06-2007



\_\_\_\_\_  
Valerie NIDDAM-HILDESHEIM

Date: 3/2/07



\_\_\_\_\_  
Tamas KOLTAI



One Broadway  
New York, NY 10004-1050  
212.425.7200  
Fax 212.425.5288

### Fax Transmission

From: **Pnina A. Rabinovich** Date: August 15, 2007  
 Direct Dial: 212.908.6467 Fax: 212.425.5288  
 Client/Matter: 1662/75605 Total number of pages: 4  
 (including cover)

*Please deliver to:*

Name	Company	Fax	Phone
<b>Recordation Services</b>	<b>USPTO</b>	<b>571 273 0140</b>	

Message:

Attached hereto is an Assignment document for Serial No. 11/788,034, to be recorded for Teva Pharmaceuticals Industries Ltd.

The Commissioner is authorized to charge the fee associated with this communication to deposit account no. 11-0600.

Original will not follow  Original will follow by  Regular Mail  Overnight Delivery  Hand Delivery

The information contained in this facsimile transmission, including any attachments, is subject to the attorney-client privilege, the attorney work product privilege or is confidential information intended only for the use of the named recipient. If the reader of this Notice is not the intended recipient or the employee or agent responsible for delivering this transmission to the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this transmission in error, please notify us immediately by telephone, so that we may arrange for its return or destruction at our cost. Thank you.

New York Washington, DC Silicon Valley [www.kenyon.com](http://www.kenyon.com)

**PATENT**

**RECORDED: 08/15/2007**

**REEL: 019701 FRAME: 0321**